Fukuda Denshi (6960) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
11 Jun, 2026Executive summary
Net sales rose 0.5% year-over-year to ¥139,697 million for the fiscal year ended March 31, 2026, with operating profit up 2.8% and profit attributable to owners up 1.0%.
The business environment remained uncertain due to global trade policies and geopolitical risks, but the company maintained growth in key segments.
Financial highlights
Operating profit reached ¥26,608 million (up 2.8% year-over-year), ordinary profit ¥27,341 million (up 2.7%), and net income ¥18,790 million (up 1.0%).
Earnings per share increased to ¥683.41 from ¥645.41 year-over-year.
Comprehensive income surged 33.5% to ¥24,238 million.
Gross profit improved to ¥76,522 million, with gross margin rising.
Outlook and guidance
Fiscal year ending March 31, 2027 forecast: net sales ¥142,000 million (+1.6%), operating profit ¥25,500 million (–4.2%), ordinary profit ¥25,500 million (–6.7%), net income ¥17,700 million (–5.8%), EPS ¥655.17.
Dividend forecast for FY2027 is ¥230 per share, with a payout ratio of 35.1%.
Latest events from Fukuda Denshi
- Slight YoY profit decline offset by strong comprehensive income and stable full-year outlook.6960
Q3 20265 Feb 2026 - Net sales up 0.8% and operating profit steady, with segment shifts and stable full-year outlook.6960
Q2 202612 Nov 2025 - Sales rose 4% year-over-year, but profits declined; full-year guidance and dividends unchanged.6960
Q1 20259 Sep 2025 - First-half profits fell on lower sales, but full-year guidance and dividend plans remain unchanged.6960
Q2 20259 Sep 2025 - Profits declined despite stable sales, with mixed segment performance and steady full-year outlook.6960
Q3 20259 Sep 2025 - Slight declines in sales and profit, with FY2026 guidance indicating further contraction.6960
Q4 20259 Sep 2025 - Profits declined despite stable sales; medical treatment and consumables segments showed growth.6960
Q1 20269 Sep 2025